Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.40 USD
Change Today -0.01 / -0.18%
Volume 128.2K
As of 11:03 AM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Douglas M. VanOort

Executive Chairman and Chief Executive Officer, Neogenomics Inc.
AgeTotal Calculated CompensationThis person is connected to 8 board members in 2 different organizations across 6 different industries.

See Board Relationships
60$928,986
As of Fiscal Year 2014

Background*

Mr. Douglas M. VanOort, also known as Doug, has been the Executive Chairman and Chief Executive Officer of Neogenomics Inc. since October 28, 2009. Mr. VanOort joined Neogenomics on March 16, 2009. Mr. VanOort serves as an Operating Partner at Summer Street Capital Partners L.L.C. He joined Neogenomics on November 1, 2004. He serves as Managing Director of Conundrum Capital Partners. He gained his business strategy, operations, finance, and organizational development ...

Read Full Background

Corporate Headquarters*

12701 Commonwealth Drive
Fort Myers, Florida 33913

United States

Phone: 239-768-0600
Fax: 239-690-4237

Board Members Memberships*

Former Director
Former Chief Executive Officer, President and Director
2009-Present
Executive Chairman and Chief Executive Officer
2009-Present
Executive Chairman and Chief Executive Officer

Education*

Unknown/Other Education
Bentley University

Other Affiliations*

Annual Compensation*

Salary$441,346
Bonus$293,968
Total Annual Compensation$735,314

Stock Options*

Restricted Stock Awards$91,000
Exercisable Options1,400,000
Unexercisable Options400,000
Total Number of Options1,800,000

Total Compensation*

Total Annual Cash Compensation$746,503
Total Short Term Compensation$735,314
Other Long Term Compensation$91,000
Total Calculated Compensation$928,986
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEO:US $5.40 USD -0.01

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Elazar Rabbani Ph.D.Co-Founder, Chairman, Chief Executive Officer and Secretary
Enzo Biochem Inc.
$555.5K
Raymond C. Kubacki Jr.Chairman, Chief Executive Officer and President
Psychemedics Corp.
$536.9K
Kenneth A. Berlin Chief Executive Officer and President
Rosetta Genomics, Ltd.
$800.0K
Thomas A. Bologna Chairman and Chief Executive Officer
Response Genetics, Inc
$767.9K
Samuel D. Riccitelli Chief Executive Officer, President and Director
Signal Genetics, Inc.
$540.0K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOGENOMICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.